LGALS3 is well-established as a mediator of glioma invasion, survival signalling, and therapeutic resistance, with its structural homology to Bcl-2 family proteins enabling anti-apoptotic activity through lactose-inhibitable interactions with Bcl-2 suppressing cytochrome C release and caspase activation, thereby enhancing chemo- and radioresistance [21]. The gene discussed is BCL2; the disease is central nervous system cancer.